Focuses on developing oral peptide therapies for autoimmune diseases and other chronic conditions by enhancing oral drug delivery.
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to advancing targeted therapies delivered orally for patients suffering from gastrointestinal disorders.
At the forefront of its innovative pipeline is latiglutenase, an oral biotherapeutic designed to break down gluten into non-immunogenic peptides, currently undergoing Phase 2 clinical studies for the treatment of celiac disease. Additionally, Entero Therapeutics is developing capeserod, a selective 5-HT4 receptor partial agonist in Phase 1 trials aimed at addressing gastroparesis.
The company is also focused on adrulipase, a recombinant lipase enzyme in Phase 2 trials intended to improve nutrient digestion for patients with exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Furthermore, Entero Therapeutics is exploring niclosamide, an oral small molecule with anti-inflammatory properties, in Phase 2 studies for the treatment of ulcerative proctitis, ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Founded in 2014 and headquartered in Boca Raton, Florida, Entero Therapeutics, Inc. (formerly known as First Wave BioPharma, Inc.) remains committed to pioneering new therapies that enhance the quality of life for patients affected by gastrointestinal diseases.